Podcast
Jonas Albert - Digital Therapeutics and the Digital Transformation
A conversation with Jonas Albert about digital therapeutics, DiGA and DiPA reimbursement, market access, evidence generation, and the institutions that decide whether digital health reaches patients.
In this conversation
Jonas Albert explains digital therapeutics and the market-access work behind reimbursable digital health products. The conversation covers what digital therapeutics are, how different countries approach reimbursement, and where business opportunities emerge.
Jonas connects product innovation with evidence generation, reimbursement logic, price negotiation, and the institutions that decide whether digital health tools reach patients.
Central question
What has to happen before a digital therapeutic becomes a reimbursed part of healthcare?
What we cover
- What digital therapeutics are and where the innovation sits.
- How Germany approaches DiGA and DiPA reimbursement pathways.
- Why evidence generation and market access strategy matter as much as the product itself.
Guest background
Jonas Albert is a market access and strategy specialist for digital health markets, with a focus on digital therapeutics and reimbursement in Germany.
Things to listen for
- How reimbursement pathways shape product strategy.
- Why digital health companies have to understand both evidence and institutions.
- Where business opportunity depends on proving value in the language of the healthcare system.
Digital therapeutics as a system
Product view
The tool solves a patient or care problem and creates a better user experience.
Access view
The tool also has to meet evidence, reimbursement, pricing, and institutional requirements.